thomas abbott iii (23 risultati)

Hardcover. Condizione: Très bon. Ancien livre de bibliothèque avec équipements. Edition 1995. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 1995. Ammareal gives back up to 15% of this item's net price to charity organizations.

Condizione: Sehr gut. Zustand: Sehr gut | Seiten: 276 | Sprache: Englisch | Produktart: Bücher | 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.

Condizione: Hervorragend. Zustand: Hervorragend | Seiten: 276 | Sprache: Englisch | Produktart: Bücher | 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.

Condizione: New. In English.

Condizione: New. In.

Condizione: New. pp. 276.

Condizione: New. pp. 276 9:B&W 6 x 9 in or 229 x 152 mm Case Laminate on Creme w/Gloss Lam.

Condizione: New. Deals in an useful way with some of the issues involved in the debate over health care reform. This book brings together some of the researchers to discuss alternative ways of restructuring the health care industries, and alternative methods for regulating these industries to achieve the objectives of increased access and constraining costs. Editor(s): Abbott III, Thomas A. Series: Topics in Regulatory Economics and Policy. Num Pages: 261 pages, biography. BIC Classification: KJU; MBP. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 229 x 152 x 19. Weight in Grams: 576. . 1995. Hardback. . . . .

Condizione: New. pp. 276.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.

Condizione: New. Deals in an useful way with some of the issues involved in the debate over health care reform. This book brings together some of the researchers to discuss alternative ways of restructuring the health care industries, and alternative methods for regulating these industries to achieve the objectives of increased access and constraining costs. Editor(s): Abbott III, Thomas A. Series: Topics in Regulatory Economics and Policy. Num Pages: 261 pages, biography. BIC Classification: KJU; MBP. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 229 x 152 x 19. Weight in Grams: 576. . 1995. Hardback. . . . . Books ship from the US and Ireland.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.

Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Hardcover. Condizione: Very Good. No Jacket. 3rd Edition. 3rd edition ; xxx, 892 p. illustrated ; LCCN: 60-5421; OCLC: 2700679 ; LC: RC961; Dewey: 616.9883; NLM: WC 680 ; green cloth ; no dustjacket ; Contents: Diseases caused by the arthropod-borne viruses -- Enterovirus infections, including poliomyelitis -- Other virus diseases of special importance or interest in tropical or subtropical areas -- Ricketsial diseases -- Epidemic typhus -- Murine typhus -- American spotted fevers -- Related spotted fevers and rickettsioses -- Rickettsialpox -- North Queensland tick typhus -- Scrub typhus -- Trench typhus -- Q fever -- Spirochetal diseases -- The relapsing fevers -- Yaws and bejel -- Pinta -- The leptospiral diseases -- Rat-bite fevers -- Sodoku --- Haverhill fever -- Bacterial diseases -- The Diarrheal diseases -- Bacillary dysentery -- shigellosis -- Food poisoning -- Botulism -- Staphylococcus -- Strptococcus -- Salmonella -- Clostridium Perfringens -- Cholera -- Brucellosis -- Tuberculosis -- Leprosy -- Plague -- Cutaneous diptheria -- Tularemia -- Mycotic diseases -- Cutaneous mycoses -- Systemic mycoses -- Protozoal diseases -- The intestinal protozoa -- Amebiasis and related infections -- Malaria -- Toxoplasmosis -- Interstitial plasma cell pneumonia -- The trypanosomidae -- Leishmaniasis -- Kala-azar -- Cutaneous leishmaniasis -- Naso-oral or mucocutaneous peishmanisis -- African trypanosomiasis -- American trypanosomiasis -- Chagas' disease -- Trypanosoma Rangeli -- Helminthic diseases -- Intestinal nematodes -- Tissue inhabiting neamtodes : the filarioidea -- Tissue-inhabiting nematodes: the dracununculoidea -- Other tissue-inhabiting nematodes -- Trichinosis -- Creeping Eruption -- Gnathostomiasis -- Visceral Larva Migrans -- The Schistosomes -- Trematodes exclusive of schistosomes -- Cestodes -- Nutritional diseases -- Pellagra -- Beriberi -- Sprue -- Kwashiorkor -- Nutritional edema -- Osteomalacia -- Vitamin A deficiency and tropical macrocytic anemia -- Miscellaneous conditions -- Epidemic hemorrhagic fever -- Bartonellosis -- tropical ulcer -- Tropical eosinophilia -- Desert sore -- Granuloma inguinale -- Effects of heat -- Heat stroke -- Heat cramps -- heat exhaustion -- Anhidrotic asthemia -- Miliaria rubra -- Certain medically impartant animals -- Coelenterates -- Leeches -- Fishes -- Lizards -- Snakes -- Corcodilians -- Bats -- Medically important mollusks -- Medically important arthropods -- The Arachnida -- The class Insecta -- The order Diptera -- Control of arthropods of medical importance -- Toxicology of pesticides -- Some laboratory diagnostic methods -- Methods and procedures. ; some color plates ; numerous black and white photographs showing symptoms of various tropical diseases ; graphic ; ex-lib, stamps, labels, date due ; VG. Book.

Condizione: new. Questo è un articolo print on demand.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns. 276 pp. Englisch.

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns. 276 pp. Englisch.

Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In c.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In c.

Buch. Condizione: Neu. Health Care Policy and Regulation | Thomas A. Abbott III | Buch | x | Englisch | 1995 | Springer US | EAN 9780792395409 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Taschenbuch. Condizione: Neu. Health Care Policy and Regulation | Thomas A. Abbott III | Taschenbuch | x | Englisch | 2012 | Humana | EAN 9781461359326 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 276 pp. Englisch.

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 276 pp. Englisch.